Evotec SE – Market Overview and Recent Developments

Current Share Price and Recent Volatility

  • On 23 April 2026 the share price fell to 5.31 €, reflecting significant selling pressure.
  • The price on 22 April 2026 was 5.68 €, about 36 % above the March level, after a strong week of activity in the United States.
  • The most recent daily close on 21 April 2026 was 5.685 €, in line with the 2026‑04‑21 intraday trading data.

Catalysts and Market Sentiment

  • Tubulis Deal: The company’s potential partnership with Tubulis is cited as a source of buying interest.
  • Conference Week in the USA: A week of active conference activity in the United States on 22 April contributed to a temporary lift in the stock.
  • Goldman Sachs Activity: Increased trading activity and new voting‑rights announcements by Goldman Sachs on 21 April heightened investor focus.
  • RBC Target: RBC analysts set a target price of 10.00 € on 21 April, indicating a bullish outlook despite current operating losses.

Index Performance Context

  • The TecDAX index, of which Evotec is a constituent, recorded mixed results in the days surrounding the price movements:
  • On 22 April it closed slightly lower, but on 23 April it ended the day in a modest loss of 0.6 %.
  • The SDAX also trended lower on 23 April, closing 0.80 % down.
  • These index movements suggest broader technology‑sector weakness, which may have amplified pressure on Evotec shares.

Company Fundamentals (as of 21 April 2026)

  • Sector: Health Care – Life Sciences Tools & Services
  • Market Capitalisation: 1 001 630 336 €
  • Price‑to‑Earnings Ratio: –9.67 (negative earnings)
  • 52‑Week Range: 3.995 € (low) – 8.566 € (high)
  • Trading Currency: EUR
  • Primary Exchange: Xetra (Germany)

Strategic Focus

Evotec SE specialises in drug‑discovery solutions across multiple therapeutic areas, including neuroscience, diabetes, pain and inflammation, oncology, infectious diseases, respiratory disorders, and fibrosis. The company supplies services to pharmaceutical and biotechnology clients worldwide and aims to develop innovative therapies addressing unmet medical needs.

Outlook

  • Short‑term: The share price is currently trading below its 52‑week low, with recent sell pressure evident.
  • Medium‑term: Positive catalysts such as the Tubulis collaboration, continued investor interest from major banks, and a bullish analyst target suggest potential for a rebound.
  • Long‑term: The company’s core expertise in life‑science services remains aligned with industry growth trends, although negative earnings and a low P/E ratio reflect current operating challenges.

All information is derived solely from the provided news excerpts and fundamental data.